|
|
Yale SPORE in Skin Cancer
|
5P50CA121974-04
|
$2,233,298
|
$558,325
|
HALABAN, RUTH
|
YALE UNIVERSITY
|
|
|
YALE COMPREHENSIVE CANCER CENTER
|
5P30CA016359-31
|
$1,889,710
|
$359,045
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
|
X-ray Targeted Therapeutic Genes within Nanoparticles
|
5R01CA125757-03
|
$46,580
|
$23,290
|
Hallahan, Dennis
|
VANDERBILT UNIVERSITY
|
|
|
X-ray Targeted Therapeutic Genes within Nanoparticles
|
7R01CA125757-04
|
$320,505
|
$160,253
|
Hallahan, Dennis
|
WASHINGTON UNIVERSITY
|
|
|
WUMC Cancer and Leukemia Group B
|
2U10CA077440-12
|
$345,040
|
$341,590
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
|
Wound Angiogenesis as a Biomarker for Tumor Angiogenesis
|
5K24CA113755-04
|
$124,659
|
$124,659
|
HURWITZ, HERBERT
|
DUKE UNIVERSITY
|
|
|
VITAMIN D PLANT ANTIOXIDANT SILIBININ IN LEUKEMIA TRANSLATIONAL STUDY
|
5R01CA117942-03
|
$189,600
|
$189,600
|
STUDZINSKI, GEORGE
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
|
|
Vitamin D in Prostate Cancer: Tumor Vasculature Effects
|
5R01CA095045-07
|
$273,560
|
$136,780
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Vitamin D and Ovarian Cancer Prevention and Treatment
|
5R01CA111334-05
|
$244,382
|
$36,657
|
BAI, WENLONG
|
UNIVERSITY OF SOUTH FLORIDA
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-26
|
$430,954
|
$181,001
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Vindoline and Vinblastine
|
5R01CA115526-04
|
$326,609
|
$326,609
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
|
|
VCU Minority-Based CCOP
|
3U10CA052784-19S1
|
$99,999
|
$45,000
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
VCU Minority-Based CCOP
|
5U10CA052784-19
|
$314,164
|
$141,374
|
Roberts, John
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
Varenicline versus Nicotine Replacement for Methadone-Maintained Smokers
|
3R01CA129226-02S1
|
$111,515
|
$55,758
|
STEIN, MICHAEL
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
|
Varenicline versus Nicotine Replacement for Methadone-Maintained Smokers
|
5R01CA129226-02
|
$505,271
|
$252,636
|
STEIN, MICHAEL
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
|
Varenicline for Smokeless Tobacco Use
|
1R21CA132621-01A1
|
$199,452
|
$199,452
|
Ebbert, Jon
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
|
Vanderbilt In Vivo Cellular and Molecular Imaging Center
|
5P50CA128323-02
|
$1,500,000
|
$165,000
|
GORE, JOHN
|
VANDERBILT UNIVERSITY
|
|
|
Validating Molecular Signature Risk Models of NSCLC
|
5R01CA116648-04
|
$455,257
|
$227,629
|
HARPOLE, DAVID
|
DUKE UNIVERSITY
|
|
|
Vaccine and radiation for the therapy of human cancers
|
ZIA BC 010975
|
$283,437
|
$283,437
|
Hodge, James
|
CCR (NCI)
|
|
|
Vaccine and Drug Combination Therapy for Human Cancers
|
ZIA BC 010661
|
$330,677
|
$165,338
|
Hodge, James
|
CCR (NCI)
|
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-36S1
|
$59,955
|
$4,197
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-36
|
$4,736,061
|
$331,524
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
|
UTMDACC SPORE in Breast Cancer
|
5P50CA116199-05
|
$2,180,817
|
$436,163
|
HORTOBAGYI, GABRIEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
UT M.D. Anderson Cancer Center Lymphoma SPORE
|
1P50CA136411-01A1
|
$500,000
|
$140,000
|
YOUNES, ANAS
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
UT M.D. Anderson Cancer Center
|
5U10CA045809-21
|
$2,091,787
|
$815,797
|
FISCH, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Using Targeted Immunotherapy to Enhance Chemotherapy of Colorectal Cancer
|
5R01CA123277-03
|
$311,600
|
$311,600
|
BEDI, ATUL
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Using Physiological Age to Predict Chemotherapy Toxicity
|
5R01CA124924-03
|
$582,693
|
$582,693
|
Mandelblatt, Jeanne
|
GEORGETOWN UNIVERSITY
|
|
|
Using Mouse Endoscopy for Evaluating Colon Cancer
|
5R01CA125691-02
|
$340,525
|
$340,525
|
Rosenberg, Daniel
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
|
Using Diazeniumdiolate Chemistry to Design Nitric Oxide-Based Therapies
|
ZIA BC 005673
|
$647,637
|
$453,346
|
Keefer, Larry
|
CCR (NCI)
|
|
|
Use p105(sr) to study p50 homodimer in skin tumor/cancer
|
5R01CA104912-06
|
$203,349
|
$203,349
|
LIN, LI
|
MEDSTAR RESEARCH INSTITUTE
|
|
|
Use of Genomic Signatures to Classify Tumors and Direct Chemotherapeutics
|
1F32CA139890-01
|
$50,054
|
$50,054
|
Gatza, Michael
|
DUKE UNIVERSITY
|
|
|
Use of CCI-779 in multiple myeloma
|
5R21CA121464-02
|
$319,950
|
$319,950
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Use of Beta-lapachone for Lung Cancer Chemotherapy
|
5R01CA102792-07
|
$341,159
|
$341,159
|
Boothman, David
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
|
Use of 2-deoxy-D-glucose & PI3K/Akt pathway inhibitors in head & neck cancer ther
|
1K01CA134941-01A1
|
$109,080
|
$109,080
|
SIMONS, ANDREAN
|
UNIVERSITY OF IOWA
|
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-34S1
|
$74,165
|
$7,417
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-34S2
|
$100,000
|
$10,000
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-34
|
$6,658,653
|
$665,865
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-25
|
$1,884,250
|
$791,385
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
|
UNRESOLVED PUBLIC HEALTH ISSUES RELATED TO HT AND CANCER
|
5P01CA017054-31
|
$1,500,330
|
$495,109
|
HENDERSON, BRIAN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S2
|
$1,678,886
|
$335,777
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S3
|
$80,987
|
$16,197
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S4
|
$99,840
|
$19,968
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-12
|
$2,300,000
|
$690,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
3P50CA083639-09S1
|
$57,442
|
$34,465
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
3P50CA083639-10S1
|
$141,526
|
$84,916
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-10
|
$2,001,032
|
$1,200,619
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
3P50CA100632-07S1
|
$52,857
|
$19,557
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
5P50CA100632-07
|
$2,300,000
|
$851,000
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-05S2
|
$60,764
|
$3,646
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO
|
|
|
University of New Mexico Cancer Center Support
|
5P30CA118100-05
|
$1,371,380
|
$82,283
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO
|
|
Total relevant funding to Chemotherapy for this search: $528,665,822
|
